Key Highlights

  • Founded in 1912, Sigma Healthcare operates as a pharmaceutical wholesale distributor and retail pharmacy franchisor in Australia and internationally.
  • It supplies pharmaceutical, medical, healthcare and beauty products to franchised community pharmacies and third parties, and provides advertising, Marketing and support services to its network.
  • It also offers MPS Connect medication management solutions.
  • The transformation came through the Merger with Chemist Warehouse, which brought together Sigma's distribution operations and one of Australia's best-known discount pharmacy brands.

The combination of pharmaceutical wholesale and a large pharmacy retail network has reshaped Sigma Healthcare’s operating scale. Sigma Healthcare (ASX:SIG) supplies pharmaceutical, medical, healthcare and beauty products while supporting pharmacy brands that include Chemist Warehouse, Amcal and Discount Drug Stores. Integration, store expansion and distribution remain central to the enlarged group.

From wholesaler to retail pharmacy

The group's retail banners now include Chemist Warehouse, Amcal and Discount Drug Stores, and the company says it operates with a presence in New Zealand, Ireland, Dubai and China. Management describes the enlarged group as approaching 1,000 pharmacies globally.

What the FY26 result and store network showed

Sigma's FY26 results were released on 27 August 2026. Revenue rose 15.5% to A$10.8 billion. Normalised EBIT climbed 20.6% to A$1,090.0 million, giving a normalised EBIT Margin of 10.1%, and normalised NPAT increased 22.3% to A$732.3 million. Net Debt stood at A$663.2 million, or 0.57 times normalised EBITDA.

On a statutory basis, FY26 Net Income of A$709.18 million and Operating Income of A$992.05 million. The statutory comparisons with FY25 show much larger percentage increases, including revenue growth of about 80%, reflecting the different basis of the comparative period following the merger. The company's own 15.5% revenue growth figure is the more like-for-like indicator of trading momentum.

The Australian segment generated revenue of A$10.4 billion, up 14.9%. Chemist Warehouse branded network sales grew 15.9%, with like-for-like sales up 13.4%. International revenue rose 33.0% to A$421.4 million, with international like-for-like sales up 12.2%. The company reported integration synergies of A$32.6 million delivered to date and said it was on track for A$100 million by FY29. Capital Expenditure for the year was A$56.7 million.

At the end of FY26, there were 561 Australian Chemist Warehouse stores, after 24 were added during the year. Offshore, the network reached 98 stores following 20 openings, including 75 in New Zealand and 18 in Ireland. The company trimmed its China presence to two stores from nine.

Dividends and director buying

Sigma declared a fully franked final Dividend of 2.0 cents per share, following a 2.0 cent Interim Dividend paid in March 2026. The company targets a Payout Ratio of 50% to 70% of NPAT.

For investors in the company, Sigma's size means it carries meaningful weight in the All Ordinaries and in the healthcare sector. Its Earnings are driven largely by consumer spending on pharmacy, health and beauty goods, supported by the Pharmaceutical Benefits Scheme framework for prescription medicines. That combination has historically given pharmacy retail a relatively defensive profile compared with discretionary retail.

Risks to keep in view

Key risks include execution of the remaining synergy programme, which the company does not expect to reach A$100 million until FY29. Regulatory settings for community pharmacy, including PBS pricing and pharmacy location rules, can influence profitability. International expansion carries operating risk. Competition from supermarkets and online retailers in health and beauty categories is another factor, as is the concentration of ownership among founding shareholders.

The Bottom Line

Sigma Healthcare is focused on executing its operating priorities while managing the company-specific risks and milestones outlined above. Progress across its core Business will shape the next phase of development.